Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

41. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol

A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol 28624096 2017 06 18 2017 06 18 1879-1913 2017 Apr 12 The American journal of cardiology Am. J. Cardiol. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or (...) Low High-Density Lipoprotein Cholesterol. S0002-9149(17)30626-4 10.1016/j.amjcard.2017.03.255 This phase 3, multiregional, randomized, double-blind, placebo-controlled study assessed the efficacy/safety profile of anacetrapib added to ongoing therapy with statin ± other lipid-modifying therapies in patients with hypercholesterolemia who were not at their low-density lipoprotein (LDL-C) goal (as per the National Cholesterol Education Program Adult Treatment Panel III guidelines) and in those

EvidenceUpdates2017

42. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p BACKGROUND: In blinded randomised controlled trials, statin therapy has been associated with few adverse events (AEs). By contrast, in observational studies, larger increases in many different AEs have been reported than in blinded trials (...) . METHODS: In the Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Trial, patients aged 40-79 years with hypertension, at least three other cardiovascular risk factors, and fasting total cholesterol concentrations of 6·5 mmol/L or lower, and who were not taking a statin or fibrate, had no history of myocardial infarction, and were not being treated for angina were randomly assigned to atorvastatin 10 mg daily or matching placebo in a randomised double-blind placebo-controlled phase

Lancet2017

43. Do statins reduce the effectiveness of the influenza vaccine?

Do statins reduce the effectiveness of the influenza vaccine? Do statins reduce the effectiveness of the influenza vaccine? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do statins reduce the effectiveness of the influenza vaccine? View/ Open Date 2017-03 Format Metadata Abstract Do statins reduce the effectiveness (...) of the influenza vaccine? Evidence-based answer: Statin therapy is associated with reduced response to influenza vaccine and decreased protection against acute respiratory illness (SOR: B, large, cross-sectional observational study and retrospective cohort study). URI Part of Citation Evidence-based practice 20, no. 3 (2017): 9 Collections hosted by hosted by

Evidence Based Practice 2017

44. Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines.

Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines. Importance: There are important differences among guideline recommendations for using statin therapy in primary prevention. New recommendations from the US Preventive Services Task Force (USPSTF) emphasize therapy based on the presence of 1 or more cardiovascular disease (CVD) risk factors and a 10-year global CVD risk of 10 (...) % or greater. Objective: To determine the difference in eligibility for primary prevention statin treatment among US adults, assuming full application of USPSTF recommendations compared with the American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Design, Setting, and Participants: National Health and Nutrition Examination Survey (NHANES) data (2009-2014) were used to assess statin eligibility under the 2016 USPSTF recommendations vs the 2013 ACC/AHA cholesterol guidelines among

JAMA2017

45. Cholesterol: slightly higher risk of type 2 diabetes with all statins

Cholesterol: slightly higher risk of type 2 diabetes with all statins Prescrire IN ENGLISH - Spotlight ''Cholesterol: slightly higher risk of type 2 diabetes with all statins'', 1 January 2017 {1} {1} {1} | | > > > Cholesterol: slightly higher risk of type 2 diabetes with all statins Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Cholesterol (...) : slightly higher risk of type 2 diabetes with all statins Several large-scale studies have revealed an increased risk of type 2 diabetes in patients taking a statin. Statins are widely used to lower cholesterol, in the hope of reducing the risk of premature death and major cardiovascular events (myocardial infarction, ischaemic stroke). A review has been carried out of 13 studies which included patient follow-up for at least one year. Some 91,000 non-diabetic participants were monitored for 4 years

Prescrire2017

46. Long-term persistence in use of statin therapy in elderly patients.

Long-term persistence in use of statin therapy in elderly patients. CONTEXT: Knowledge of long-term persistence with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) therapy is limited because previous studies have observed patients for short periods of time, in closely monitored clinical trials, or in other unrepresentative settings. OBJECTIVE: To describe the patterns and predictors of long-term persistence with statin therapy in an elderly US population. DESIGN, SETTING (...) , AND PATIENTS: Retrospective cohort study including 34 501 enrollees in the New Jersey Medicaid and Pharmaceutical Assistance to the Aged and Disabled programs who were 65 years of age and older, initiated statin treatment between 1990 and 1998, and who were followed up until death, disenrollment, or December 31, 1999. MAIN OUTCOME MEASURES: Proportion of days covered (PDC) by a statin in each quarter during the first year of therapy and every 6 months thereafter; predictors of suboptimal persistence during

JAMA2017

47. Adherence with statin therapy in elderly patients with and without acute coronary syndromes.

Adherence with statin therapy in elderly patients with and without acute coronary syndromes. CONTEXT: Landmark clinical trials have demonstrated the survival benefits of statins, with benefits usually starting after 1 to 2 years of treatment. Research prior to these trials of older lipid-lowering agents demonstrated low levels of 1-year adherence. OBJECTIVE: To compare 2-year adherence following statin initiation in 3 cohorts of patients: those with recent acute coronary syndrome (ACS), those (...) with chronic coronary artery disease (CAD), and those without coronary disease (primary prevention). DESIGN AND SETTING: Cohort study using linked population-based administrative data from Ontario. PATIENTS: All patients aged 66 years or older who received at least 1 statin prescription between January 1994 and December 1998 and who did not have a statin prescription in the prior year were followed up for 2 years from their first statin prescription. There were 22,379 patients in the ACS, 36,106

JAMA2017

48. Non-Statin Therapies For LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

Non-Statin Therapies For LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

American College of Cardiology2017

49. Statins for primary and secondary prevention of cardiovascular disease

Statins for primary and secondary prevention of cardiovascular disease

DynaMed Plus2017

53. Perspective on Trends in Statin Use

Perspective on Trends in Statin Use 27842177 2018 11 13 2380-6591 2 1 2017 Jan 01 JAMA cardiology JAMA Cardiol Perspective on Trends in Statin Use. 11-12 10.1001/jamacardio.2016.4710 Weintraub William S WS Christian Care Health System, Newark, Delaware. eng U54 GM104941 GM NIGMS NIH HHS United States Journal Article United States JAMA Cardiol 101676033 2016 11 15 6 0 2016 11 15 6 0 2016 11 15 6 0 ppublish 27842177 2583423 10.1001/jamacardio.2016.4710 PMC5621636 NIHMS863753 Health Aff (Millwood

JAMA cardiology2017 Full Text: Link to full Text with Trip Pro

54. Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study

Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study 27943058 2018 11 13 2199-1154 4 1 2017 Mar Drugs - real world outcomes Drugs Real World Outcomes Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study. 9-19 10.1007/s40801-016-0101-6 Disease-modifying drugs are not yet available for the management of chronic obstructive pulmonary disease (COPD). HMG-CoA reductase inhibitors (statins) have anti (...) -inflammatory properties and are therefore being considered for use in the management of COPD. Our objective was to examine the association between statin use and COPD-specific outcomes in a real-world setting. This was a retrospective longitudinal dynamic cohort study that used Medicaid claims data from multiple years (2005-2008) to identify patients with newly diagnosed COPD. Statin therapy was determined from the prescription drug file using National Drug Codes (NDCs). COPD-specific outcomes such

Drugs - real world outcomes2016 Full Text: Link to full Text with Trip Pro

55. Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis

Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis 27900570 2018 11 13 2198-6576 4 1 2017 Jun Rheumatology and therapy Rheumatol Ther Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis. 133-149 10.1007/s40744-016-0049-8 Patients with rheumatoid arthritis (RA) have decreased survival because of increased cardiovascular risk compared with the general population, and treatment (...) with tocilizumab (TCZ) has been shown to increase lipid levels; however, the relationship between lipids and cardiovascular risk is unknown. This post hoc analysis expanded on previously reported 24-week results by characterizing statin use and subsequent changes in lipid parameters in patients with RA treated with intravenous or subcutaneous TCZ (TCZ-IV or TCZ-SC) over 2 years of treatment. Data were collected from patients with moderate to severe active RA who received ≥1 dose of the study drug in seven

Rheumatology and therapy2016 Full Text: Link to full Text with Trip Pro

56. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Importance: Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin therapy reduces progression of coronary atherosclerosis in proportion to achieved LDL-C levels. Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incremental LDL-C lowering in statin-treated patients; however, the effects of these drugs on coronary (...) atherosclerosis have not been evaluated. Objective: To determine the effects of PCSK9 inhibition with evolocumab on progression of coronary atherosclerosis in statin-treated patients. Design, Setting, and Participants: The GLAGOV multicenter, double-blind, placebo-controlled, randomized clinical trial (enrollment May 3, 2013, to January 12, 2015) conducted at 197 academic and community hospitals in North America, Europe, South America, Asia, Australia, and South Africa and enrolling 968 patients presenting

JAMA2016

57. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. Importance: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults. Objective: To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults. Evidence Review: The USPSTF reviewed the evidence on the benefits (...) and harms of screening for and treatment of dyslipidemia in adults 21 years and older; the benefits and harms of statin use in reducing CVD events and mortality in adults without a history of CVD events; whether the benefits of statin use vary by subgroup, clinical characteristics, or dosage; and the benefits of various treatment strategies in adults 40 years and older without a history of CVD events. Conclusions and Recommendations: The USPSTF recommends initiating use of low- to moderate-dose statins

JAMA2016

58. Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence

Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence 27838724 2016 12 13 2018 11 13 1538-3598 316 19 2016 Nov 15 JAMA JAMA Statins for Primary Prevention in Older Adults: Uncertainty and the Need for More Evidence. 1971-1972 10.1001/jama.2016.15212 Gurwitz Jerry H JH Meyers Primary Care Institute, a joint endeavor of University of Massachusetts Medical School, Fallon Health, and Reliant Medical Group, Worcester, Massachusetts2Division of Geriatric Medicine

JAMA2016 Full Text: Link to full Text with Trip Pro

59. Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study

Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study 27585686 2016 09 02 2016 12 02 0315-162X 43 12 2016 Dec The Journal of rheumatology J. Rheumatol. Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis: Effect of Statin Exposure. A French Population-based Study. 2162-2170 To identify predictors and protectors for cardiovascular hospitalization in a giant cell arteritis (GCA) population-based cohort (...) daily dose of statins (HR 0.993, 0.986-0.999) were independent predictors for subsequent cardiovascular hospitalization. None of the 25 patients with GCA who were taking platelet aggregation inhibitors experienced a cardiovascular hospitalization during followup. Patients with GCA present a high risk of cardiovascular hospitalization after diagnosis. In patients with incident GCA from the Midi-Pyrenees region, southern France, statin therapy was associated with reduced cardiovascular

EvidenceUpdates2016

60. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia

Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia 27756478 2016 10 19 2017 05 01 2017 05 01 1879-1913 118 12 2016 Dec 15 The American journal of cardiology Am. J. Cardiol. Effect on Fasting Serum Glucose Levels of Adding Ezetimibe to Statins in Patients With Nondiabetic Hypercholesterolemia. 1812-1820 S0002-9149(16)31478-3 10.1016/j.amjcard.2016.08.071 Statin therapy is associated with a slightly increased risk of developing (...) diabetes mellitus and insulin resistance in patients without diabetes. Ezetimibe combined with statins may be considered for high-risk patients who do not achieve optimal low-density lipoprotein cholesterol lowering on statin monotherapy or who are statin intolerant. Changes in fasting serum glucose (FSG) levels during ezetimibe, ezetimibe/statin, and statin treatments were assessed using data pooled from clinical trials in hypercholesterolemic and heterozygous familial hypercholesterolemic patients

EvidenceUpdates2016